Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
2(9%)
Results Posted
33%(5 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_3
1
5%
Ph phase_1
9
41%
Ph phase_2
12
55%

Phase Distribution

9

Early Stage

12

Mid Stage

1

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
9(40.9%)
Phase 2Efficacy & side effects
12(54.5%)
Phase 3Large-scale testing
1(4.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

15 of 20 finished

Non-Completion Rate

25.0%

5 ended early

Currently Active

2

trials recruiting

Total Trials

22

all time

Status Distribution
Active(2)
Completed(15)
Terminated(5)

Detailed Status

Completed15
Withdrawn4
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
2
Success Rate
93.8%
Most Advanced
Phase 3

Trials by Phase

Phase 19 (40.9%)
Phase 212 (54.5%)
Phase 31 (4.5%)

Trials by Status

terminated15%
withdrawn418%
active_not_recruiting29%
completed1568%

Recent Activity

2 active trials
Showing 5 of 22
active_not_recruitingphase_2

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

NCT04150900
active_not_recruitingphase_2

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

NCT03519997
completedphase_2

Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

NCT03139916
terminatedphase_2

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

NCT05249569
completedphase_2

An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

NCT04099641
View all 22 trials

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT04150900Phase 2

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Active Not Recruiting
NCT03519997Phase 2

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Active Not Recruiting
NCT03139916Phase 2

Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Completed
NCT05249569Phase 2

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

Terminated
NCT04099641Phase 2

An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

Completed
NCT01634685Phase 1

A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma

Completed
NCT02989870Phase 1

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Withdrawn
NCT01323062Phase 1

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

Completed
NCT02651610Phase 2

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Withdrawn
NCT01999673Phase 3

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

Completed
NCT00669591Phase 2

A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

Completed
NCT01272791Phase 2

Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Completed
NCT01160601Phase 2

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Completed
NCT02685306Phase 2

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Withdrawn
NCT02673814Phase 2

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Withdrawn
NCT01288261Phase 1

Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer

Completed
NCT01273948Phase 1

Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

Completed
NCT00503347Phase 1

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

Completed
NCT00669565Phase 2

Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer

Completed
NCT00129337Phase 1

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22